1-9 of 9
Charles J. Sherr, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Mark Blaine Geyer, MD, Patrick W. Burke, MD, Amber C. King, PharmD, BCOP, Michael J. Mauro, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Charles J. Sherr, MD PhD, Dan Douer, MD, Jae H. Park, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2692.
https://doi.org/10.1182/blood-2018-99-110537
Published: 2018
Journal Articles

Prevention Of Minimal Residual Disease In Ph+ ALL

Iris Appelmann, MD, Elisa DeStanchina, PhD, Gregory Carbonetti, BS, Chong Chen, PhD, Scott W. Lowe, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1265.
https://doi.org/10.1182/blood.V122.21.1265.1265
Published: 2013
Journal Articles

Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness

Laura B. Ramsey, PhD, Laura Janke, DVM, PhD, Mathew Edick, PhD, Cheng Cheng, PhD, Richard T Williams, MBBS, PhD, Charles J. Sherr, MD, PhD, William E. Evans, PharmD, Mary V. Relling, PharmD
Journal: Blood
Blood (2012) 120 (21): 3560.
https://doi.org/10.1182/blood.V120.21.3560.3560
Published: 2012
Journal Articles

Developmentally Restricted Protection From Notch1-Induced T Cell Acute Lymphoblastic Leukemia by the Arf Tumor Suppressor.

Emmanuel Volanakis, MD, Richard T Williams, MD, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 143.
https://doi.org/10.1182/blood.V114.22.143.143
Published: 2009
Journal Articles

Acquired Bcr-Abl Kinase Domain Mutations Are Not Responsible for Persistence of Dasatinib-Refractory Disease in Murine Ph+ ALL

Nidal Boulos, PhD, Charles J. Sherr, MD, PhD, Richard T Williams, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2924.
https://doi.org/10.1182/blood.V112.11.2924.2924
Published: 2008
Journal Articles

Ultra-High Resolution Analysis of Genomic Alterations in High-Risk Acute Lymphoblastic Leukemia.

Charles G Mullighan, MBBS(Hons), MSc, MD, Letha A. Phillips, BS, Lesli A. Kiedrowski, Jing Ma, PhD, Richard T. Williams, MD, PhD, Sheila A. Shurtleff, Charles J. Sherr, MD, PhD, James R. Downing, MD
Journal: Blood
Blood (2008) 112 (11): 2053.
https://doi.org/10.1182/blood.V112.11.2053.2053
Published: 2008
Journal Articles

Cytokine-Dependent Imatinib Resistance in Mouse Bcr-Abl(+), Arf -Null Lymphoblastic Leukemia.

Richard T. Williams, MD, PhD, Willem den Besten, PhD, Nidal Boulos, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2632.
https://doi.org/10.1182/blood.V110.11.2632.2632
Published: 2007
Journal Articles

Inactivation of the Arf Tumor Suppressor in Mouse BCR-ABL(+) B Cells Greatly Increases the Frequency of Leukemia-Initiating Cells and Confers Imatinib Resistance In Vivo .

Richard T. Williams, MD, PhD, Charles J. Sherr, MD PhD
Journal: Blood
Blood (2006) 108 (11): 385.
https://doi.org/10.1182/blood.V108.11.385.385
Published: 2006
Journal Articles

Genetic Interaction of the BCR-ABL Oncogene and the ARF Tumor Suppressor in Ph+ Lymphoid Leukemia.

Richard T. Williams, MD, PhD, Martine F. Roussel, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 240.
https://doi.org/10.1182/blood.V106.11.240.240
Published: 2005